These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11475271)

  • 21. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
    Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
    Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [From insulin secretion to insulin therapy].
    Soltani D; Perlemuter L
    Presse Med; 1998 Jul 4-11; 27(24):1240-6. PubMed ID: 9767787
    [No Abstract]   [Full Text] [Related]  

  • 24. [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
    Li JW; Tian HM; Yu HL; Zhang XX; Zhao GZ; Wang JN
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):267-70. PubMed ID: 15807285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe hypoglycaemia from repaglinide-brotizolam drug interaction: a case report and literature review.
    Khamaisi M
    Diabet Med; 2012 Sep; 29(9):1214-5. PubMed ID: 22414218
    [No Abstract]   [Full Text] [Related]  

  • 26. Insulin responses to sulfonylureas.
    Cerasi E
    Diabetes Res Clin Pract; 2002 Apr; 56(1):69-70; author reply 71. PubMed ID: 11879723
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination therapy in type 2 diabetes: the role of repaglinide.
    Moses R
    J Assoc Physicians India; 2001 Jan; 49 Spec No():62-8. PubMed ID: 11235608
    [No Abstract]   [Full Text] [Related]  

  • 28. Improving management of type 2 diabetes mellitus: 4. Meglitinides.
    Quillen DM; Kuritzky L; Samraj GP
    Hosp Pract (1995); 1999 Dec; 34(13):38-40. PubMed ID: 10611897
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
    Wang Y; Zhao L; Huang Q; Peng Y
    J Diabetes; 2014 Mar; 6(2):164-6. PubMed ID: 23879890
    [No Abstract]   [Full Text] [Related]  

  • 30. Honing type 2 diabetes treatment.
    Blackburn G
    Health News; 2001 Jan; 7(1):1-2. PubMed ID: 11198405
    [No Abstract]   [Full Text] [Related]  

  • 31. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?
    Reaven GM
    Diab Vasc Dis Res; 2009 Apr; 6(2):133-8. PubMed ID: 20368203
    [No Abstract]   [Full Text] [Related]  

  • 32. Insulinotropic meglitinide analogues.
    Dornhorst A
    Lancet; 2001 Nov; 358(9294):1709-16. PubMed ID: 11728565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twelve weeks' treatment with diazoxide without insulin supplementation in Type 2 diabetes is feasible but does not improve insulin secretion.
    Radtke M; Kollind M; Qvigstad E; Grill V
    Diabet Med; 2007 Feb; 24(2):172-7. PubMed ID: 17257280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes.
    Meneilly GS
    Diabetes Technol Ther; 2011 Jan; 13(1):63-5. PubMed ID: 21175273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repaglinide for type 2 diabetes mellitus.
    Med Lett Drugs Ther; 1998 May; 40(1027):55-6. PubMed ID: 9618664
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.
    Strange P; Schwartz SL; Graf RJ; Polvino W; Weston I; Marbury TC; Huang WC; Goldberg RB
    Diabetes Technol Ther; 1999; 1(3):247-56. PubMed ID: 11475269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
    Rutten GE
    Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1547-50. PubMed ID: 11525087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous glucose monitoring: physiologic and pathophysiologic significance.
    Ionescu-Tîrgovişte C; Guja C; Ioacără S; Dumitrescu D; Tomescu I
    Rom J Intern Med; 2004; 42(2):381-93. PubMed ID: 15529628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug knowledge is critical.
    Lilley LL; Guanci R
    Am J Nurs; 1998 Jul; 98(7):14. PubMed ID: 9663123
    [No Abstract]   [Full Text] [Related]  

  • 40. [Flexible oral therapy of diabetes mellitus type 2: dietary glucose regulation as therapeutic principle. 34th annual session of the European Association for the Study of Diabetes (EASD). Barcelona, 8-12 September 1998].
    Dtsch Med Wochenschr; 1998 Dec; 123(50 Suppl Flexible):1-4. PubMed ID: 9883267
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.